All In Biotech

Free tool

FAERS Monitor: Xospata

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211349 or its brand name (Xospata, Gilteritinib Fumarate). Reports on generic versions are filed under their own applications.

Reports

4,079

Serious

3,848

94% of reports

Hospitalization

1,367

Death reported

1,051

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use508
  • acute myeloid leukaemia342
  • myelosuppression312
  • platelet count decreased298
  • pneumonia282
  • death273
  • pyrexia261
  • product use issue254
  • febrile neutropenia252
  • acute myeloid leukaemia recurrent180
  • cytopenia167
  • infection161
  • thrombocytopenia152
  • drug ineffective151
  • neutropenia144

Reports by year received

View as table
YearReports
20161
20174
20188
2019186
2020359
2021578
2022628
2023619
2024599
2025645
2026452

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,080 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
acute myeloid leukaemia recurrentSignal180471.8406.377,053
acute myeloid leukaemiaSignal342115.7104.437,940
cytopeniaSignal16771.361.411,353
myelosuppressionSignal31245.040.513,301
febrile neutropeniaSignal25219.717.44,442
platelet count decreasedSignal29814.513.03,727
thrombocytopeniaSignal1527.06.0781
product use issueSignal2547.06.21,304
infectionSignal1615.74.9629
neutropeniaSignal1445.54.7524
pneumoniaSignal2824.54.0774
pyrexiaSignal2613.93.5567
off label useSignal5083.02.8701
death2731.61.569
drug ineffective1510.60.545

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.